The Topol review of digital training needs for the NHS is published today. It says that cross-sector collaboration is vital - Andrew Croydon, Director of Skills and Education policy at the ABPI, agrees.
A Europe-wide initiative to protect patients and public health from falsified or fake medicines goes live on Saturday 9 February 2019, making the medicines supply chain across Europe safer than ever before.
The Chancellor has announced a £100 million investment for research and technology.
As the UK prepares to leave the EU, the House of Lords is debating a Statutory Instrument which would weaken the UK’s IP framework and damage the country’s reputation as leader in life sciences.
Lisa Anson, President of the ABPI, closing remarks to the ABPI Annual Conference on the future of UK life sciences.
Mike Thompson, chief executive of the ABPI, opening address to the ABPI Annual Conference outlining the strength of the industry and looking ahead to the next 70 years.
A report published by the Business, Energy and Indsutrial Strategy (BEIS) Strategy Committee, calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry.
In a speech today, the Prime Minister Theresa May will set out plans for artificial intelligence (AI) to help to prevent 22,000 cancer deaths each year by 2033.
The Department of Health and Social Care has committed £30 million to fight global AMR, delivered through 4 new projects as part of the Global AMR Innovation Fund (GAMRIF).
The European Commission have published proposals for how it will allocate its budget for science spending in the next EU budget. The funding programme - Horizon Europe - is the successor to Horizon 2020 and covers the period 2021-2027.
A new £56 million UK innovation centre, set to revolutionise how medicines are manufactured, is to be located in Renfrewshire, Scotland, allowing the UK to capture a bigger slice of the global £98 billion small molecule pharma market.